Epidermal Growth Factor Receptor and Notch Signaling in Non-small-cell Lung Cancer

Overview

Journal Cancer Med

Specialty Oncology

Date 2016 Oct 23

PMID 27770511

Citations 25

Authors

Joanna Pancewicz-Wojtkiewicz

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the most common reason of cancer deaths and about 85% of these are non-small-cell lung cancer. Currently, lung cancer therapy is mainly based on the tumor node metastasis (TNM) disease staging and tumor histological classification. Despite therapeutic innovations, the prognosis for lung cancer patients has not significantly changed in the last years. Therefore, a proper understanding of cell signaling pathways involved in cancer pathogenesis seems to be essential for improvement in cancer therapy field. The knowledge of crosstalk between epidermal growth factor receptor (EGFR) and Notch pathway can lead to enhanced screening for the expression of these genes allowing patients to optimize treatment options and predict potential treatment resistance. This review focuses on recent advances related to the mechanisms of EGFR and Notch signaling in non-small-cell lung cancer and the effectiveness of current Notch- and EGFR-targeted therapies.

Citing Articles

Discovery of paradoxical genes: reevaluating the prognostic impact of overexpressed genes in cancer.

Liu D, Liu L, Che X, Wu G Front Cell Dev Biol. 2025; 13:1525345.

PMID: 39911323 PMC: 11794808. DOI: 10.3389/fcell.2025.1525345.

Assessing the causal relationship between non-small cell lung cancer and sepsis: a Mendelian randomization study.

Cheng H, Wang X, Yao J, Guo N, Liu J BMC Cancer. 2024; 24(1):1233.

PMID: 39375649 PMC: 11457449. DOI: 10.1186/s12885-024-13003-0.

Inferring ligand-receptor cellular networks from bulk and spatial transcriptomic datasets with BulkSignalR.

Villemin J, Bassaganyas L, Pourquier D, Boissiere F, Cabello-Aguilar S, Crapez E Nucleic Acids Res. 2023; .

PMID: 37144485 PMC: 10250239. DOI: 10.1093/nar/gkad352.

Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway.

Vanaroj P, Chaijaroenkul W, Na-Bangchang K Asian Pac J Cancer Prev. 2023; 24(2):551-558.

PMID: 36853304 PMC: 10162598. DOI: 10.31557/APJCP.2023.24.2.551.

The Signaling Pathways and Targets of Natural Compounds from Traditional Chinese Medicine in Treating Ischemic Stroke.

Li X, Yin F, Zhou X, Zhang A, Sun H, Yan G Molecules. 2022; 27(10).

PMID: 35630576 PMC: 9148018. DOI: 10.3390/molecules27103099.

References

Lopes G, Vattimo E, de Castro Junior G . Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancer. J Bras Pneumol. 2015; 41(4):365-75. PMC: 4635957. DOI: 10.1590/S1806-37132015000004531. View

Adamo V, Franchina T, Adamo B, Denaro N, Gambadauro P, Chiofalo G . Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives. Cancer Biol Ther. 2009; 8(3):206-12. DOI: 10.4161/cbt.8.3.7465. View

Protsenko S, Rudakova A . [Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis]. Vopr Onkol. 2015; 61(4):676-80. View

Kolev V, Mandinova A, Guinea-Viniegra J, Hu B, Lefort K, Lambertini C . EGFR signalling as a negative regulator of Notch1 gene transcription and function in proliferating keratinocytes and cancer. Nat Cell Biol. 2008; 10(8):902-11. PMC: 2747621. DOI: 10.1038/ncb1750. View

Giannopoulou E, Nikolakopoulos A, Kotsirilou D, Lampropoulou A, Raftopoulou S, Papadimitriou E . Epidermal growth factor receptor status and Notch inhibition in non-small cell lung cancer cells. J Biomed Sci. 2015; 22:98. PMC: 4619334. DOI: 10.1186/s12929-015-0196-1. View

Pennell N, Lynch Jr T . Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC. Oncologist. 2009; 14(4):399-411. DOI: 10.1634/theoncologist.2008-0276. View

Yamaguchi H, Chang S, Hsu J, Hung M . Signaling cross-talk in the resistance to HER family receptor targeted therapy. Oncogene. 2013; 33(9):1073-81. PMC: 3874419. DOI: 10.1038/onc.2013.74. View

Dahabreh I, Linardou H, Siannis F, Kosmidis P, Bafaloukos D, Murray S . Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2009; 16(1):291-303. DOI: 10.1158/1078-0432.CCR-09-1660. View

Doroquez D, Rebay I . Signal integration during development: mechanisms of EGFR and Notch pathway function and cross-talk. Crit Rev Biochem Mol Biol. 2006; 41(6):339-85. DOI: 10.1080/10409230600914344. View

10.

Aita M, Fasola G, Defferrari C, Brianti A, Dal Bello M, Follador A . Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 2008; 68(3):183-96. DOI: 10.1016/j.critrevonc.2008.05.002. View

11.

Pancewicz J, Nicot C . Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer. 2011; 11:502. PMC: 3262490. DOI: 10.1186/1471-2407-11-502. View

12.

Cheng L, Zhang S, Alexander R, Yao Y, MacLennan G, Pan C . The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. Future Oncol. 2011; 7(4):519-41. DOI: 10.2217/fon.11.25. View

13.

Tsiambas E, Ragos V, Lefas A, Georgiannos S, Grapsa D, Patsouris E . Chromosome 7 deregulation in non-small cell lung carcinoma molecular landscape. J BUON. 2016; 20(6):1635-9. View

14.

Brizzi M, Defilippi P . Dll4/Notch1 signaling from tip/stalk endothelial cell specification to stroma-dependent lung tumor inhibition: a flavor of Dll4/Notch1 pleiotropy in tumor cell biology. Transl Lung Cancer Res. 2015; 2(6):466-9. PMC: 4367631. DOI: 10.3978/j.issn.2218-6751.2013.10.18. View

15.

Russo A, Franchina T, Ricciardi G, Picone A, Ferraro G, Zanghi M . A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015; 6(29):26814-25. PMC: 4694955. DOI: 10.18632/oncotarget.4254. View

16.

Pancewicz-Wojtkiewicz J . Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer. Cancer Med. 2016; 5(12):3572-3578. PMC: 5224843. DOI: 10.1002/cam4.944. View

17.

Ciardiello F, Tortora G . EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358(11):1160-74. DOI: 10.1056/NEJMra0707704. View

18.

Endoh H, Ishibashi Y, Yamaki E, Yoshida T, Yajima T, Kimura H . Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. Lung Cancer. 2008; 63(2):241-6. DOI: 10.1016/j.lungcan.2008.05.013. View

19.

Liu L, Li F, Pao W, Michor F . Dose-Dependent Mutation Rates Determine Optimum Erlotinib Dosing Strategies for EGFR Mutant Non-Small Cell Lung Cancer Patients. PLoS One. 2015; 10(11):e0141665. PMC: 4633116. DOI: 10.1371/journal.pone.0141665. View

20.

Reade C, Ganti A . EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab. Biologics. 2009; 3:215-24. PMC: 2726075. View